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Introduction: Animal studies have reported that treatment with angiotensin II receptor blockers reduced kidney
sodium-dependent glucose cotransporter expression. We therefore hypothesized that patients with hypertension
treated with an angiotensin II receptor blocker (candesartan) would probably have an increased response to
sodium-dependent glucose cotransporter inhibitor therapy (ipragliflozin) compared with patients treated with
alternative hypertensive medications such as calcium channel blockers (nifedipine).
Although sodium-dependent glucose cotransporter inhibitor (ipragliflozin) is a new anti-diabetic medicine, the
clinical efficacy in the Japanese population has not been fully evaluated. We compared the combined effect of
angiotensin II receptor blocker candesartan plus ipragliflozin with nifedipine plus ipragliflozin therapy and found
that the combination of candesartan plus ipragliflozin was more effective in increasing glycosuria and lowering
plasma glucose.
Case presentation: A 57-year-old Japanese man with essential hypertension was treated with candesartan.
Candesartan was switched to nifedipine for the initial 10 days of an observation period and 5 days later he was
started on ipragliflozin (day 6 of nifedipine treatment) with nifedipine for the next 5 days. Thereafter (from day
11 to day 20), candesartan was started instead of nifedipine and ipragliflozin was continued. In the last 5 days
ipragliflozin was stopped and he was treated with candesartan alone. Neither nifedipine alone (0.038+/−0.004)
nor candesartan alone (0.048+/−0.006) produce any trace amount of glycosuria. However, the extent of glycosuria
under ipragliflozin with candesartan treatment (37.5+/−8.45) was significantly greater than that of ipragliflozin
with nifedipine (23.75+/−0.35; P<0.05).
Conclusion: Candesartan demonstrated additive actions with ipragliflozin to increase glycosuria compared to
ipragliflozin with nifedipine treatment.
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Sodium-dependent glucose cotransporter 2 (SGLT2) in-
hibitors are a new class of anti-diabetic agents and are
currently attracting clinicians’ attention in our country,
Japan [1]. However, there is a scarcity of information on
the effectiveness of SGLT2 inhibitors in the Japanese
population. Angiotensin II receptor blockers (ARBs) reduce
aldosterone secretion by mainly antagonizing the angio-* Correspondence: okadash@gunma-u.ac.jp
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unless otherwise stated.tensin I receptor but are less likely to regulate glucose
reabsorption in the kidney [2]. Nevertheless, three case
reports have indicated that angiotensin-converting enzyme
(ACE) inhibitor resulted in glycosuria without any other
side effects including kidney dysfunction [3]. Thus, we
hypothesized that ACE inhibition may increase glycosuria
through actions on the angiotensin II receptor and reduc-
tion of SGLT2 levels in hypertensive patients. To compare
directly the effect of the combination of ipragliflozin
and nifedipine with the combination of ipragliflozin
and candesartan, we treated the same hypertensiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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observed a further increase in glycosuria with the com-
bination therapy of ipragliflozin and candesartan. This
is the first case report to show the direct comparison of
the combination therapy of ipragliflozin and candesartan
and the combination of ipragliflozin and nifedipine on
glycosuria in the same hypertensive man.
Case presentation
A 57-year-old Japanese man with essential hypertension
diagnosed 2 years earlier was treated with candesartan
(8mg/day) following the initial diagnosis. He did not have
any complications including diabetes mellitus except for
essential hypertension based on annual comprehensive
medical check-up. After he gave informed consent, cande-
sartan (8mg/day) was switched to nifedipine (10mg/day)
for the initial 10 days of an observation period (Figure 1,
indicated by pink color bar) and 5 days later he was
started on ipragliflozin (day 6 of nifedipine treatment;
50mg/day) with nifedipine after breakfast for the next 5
days (Figure 1, indicated by green color bar). Thereafter
(from day 11 to day 20), candesartan (8mg/day) was
started instead of nifedipine (Figure 1, indicated by blue
color bar) and ipragliflozin was continued. For the last
5 days of candesartan treatment the ipragliflozin was
stopped (Figure 1) and he was treated with candesartan
alone.
Approximately 3.5 hours after breakfast random urine
and blood samples were collected as indicated in the
schedule shown in Figure 1. According to the drug
pharmacokinetics data, nifedipine is rapidly absorbed,
reaching maximum plasma concentration within 3 hours
and returns to basal level within 24 hours [4]. Therefore,
we collected urine samples at days 3, 4, and 5 and a
blood sample at day 5 of nifedipine treatment. Ipragliflo-
zin is also rapidly absorbed, reaching maximum plasma
concentration within 3 hours [5]. The plasma half-life of
ipragliflozin is 10.0 to 13.3 hours following an initial dose of
ipragliflozin [5]. Therefore, we collected urine samples at
days 8, 9, and 10 and a blood sample at day 10 for the com-
bined ipragliflozin plus nifedipine treatments. Candesartan
reaches maximum plasma concentration within 6 hoursFigure 1 Schedule of drug administration and sample collection. Brief
the initial 10 days of the observation period (indicated by pink color bar) and
after breakfast for the next 5 days (indicated by green color bar). Thereafter, c
by blue color bar) and ipragliflozin was continued. In the last 5 days ipraglifloz
Abbreviations: exam., examination.with recovery to basal level within 24 hours [6]. Urine was
collected at days 13, 14, and 15 and a blood sample at day
15 for the combination of ipragliflozin with candesartan
treatments. We also collected urine samples at days 18,
19, and 20 and a blood sample at day 20 for candesartan
treatment alone. The blood samples were immediately
centrifuged at room temperature and serum was stored
at −80°C. The clinical laboratory test was submitted to
Special Reference Laboratories (Tokyo, Japan). Glyco-
suria was calculated as mean+/−standard deviation from
three independent samples and statistical analysis was
performed to determine statistical differences between
the means with a P value less than 0.05 for statistical
significance by InStat 2.00 program.
As shown in Figure 2, after 3 hours (B) from the initial
ipragliflozin administration (A) there was an increase in
glycosuria that returned to normal basal level by 48
hours from the last ipragliflozin administration (C). How-
ever, there was no significant effect on systolic (nifedipine,
calcium channel blocker, CCB, alone, 134.5+/−2.65; ipra-
gliflozin with CCB, 133.5+/−3.7; ipragliflozin with ARB,
candesartan, 123.25+/−2.63; ARB alone, 134.25+/−4.64)
or diastolic blood pressure (CCB alone, 85+/−6.68;
ipragliflozin with CCB, 88+/−4.97; ipragliflozin with
ARB, 80+/−3.56; ARB alone, 84+/−2.45; Figure 2 and
Table 1). Throughout the entire observation period we
did not observe any adverse effect and there were no
detectable hypotensive episodes
A summary of the blood examination is shown in
Table 1. There were no significant changes in his blood
glucose, insulin, glycoalbumin, blood urea nitrogen cre-
atinine, estimated glomerular filtration rate (CCB alone,
60.1; ipragliflozin with CCB, 58.2; ipragliflozin with ARB,
60.1; ARB alone; 66.6), potassium, and chlorine through-
out the observation period. In addition, his albuminuria
index remained within the normal range through the
observation period (data not shown).
In Figure 3 we show the change in glycosuria. We con-
firmed that neither nifedipine alone (0.038+/−0.004) nor
candesartan alone (0.048+/−0.006) produce any trace
amount of glycosuria and this is consistent with glycoal-
bumin value indication without diabetes mellitus (Table 1ly, candesartan (8mg/day) was switched to nifedipine (10mg/day) for
5 days later he started to take ipragliflozin (50mg/day) with nifedipine
andesartan (8 mg/day) was started again instead of nifedipine (indicated




Figure 2 Change of blood pressure and glycosuria. Closed square indicates systolic pressure and closed circle indicates diastolic pressure in
the upper panel. In the lower panel glycosuria is indicated by an arrow. Abbreviations: ARB, angiotensin II receptor blocker; CCB, calcium channel
blocker; SGLT2, sodium-dependent glucose cotransporter 2.
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ipragliflozin with candesartan treatment (37.5+/−8.45)
was significantly greater than that of ipragliflozin with
nifedipine (23.75+/−0.35; Figure 3, P<0.05).
Discussion
This report describes a very important clinical observa-
tion that patients treated with an ARB (candesartan) willTable 1 Blood chemistry results










Abbreviations: BS blood suger, BUN blood urea nitrogen, Cl chlorine; eGFR estimated
K potassium, Na sodium, SCr serum creatinine.probably have an increased response to SGLT2 inhibitor
therapy (ipragliflozin) compared with patients treated
with alternative hypertensive medications such as CCBs
(nifedipine). Although CCBs are not known to modulate
SGLT2 function, ARB was recently reported to downreg-
ulate SGLT2 expression in a hypertension rat model
[7]. Thus, care must be taken to carefully monitor pa-










glomerular filtration rate, GA glycoalbumin, IRI immunoreactive insulin,
Figure 3 Change of glycosuria. In the lower panel Y axis indicates
the value of glycosuria calculated as that urine sugar was divided by
urine creatinine. Abbreviations: ARB, angiotensin II receptor blocker; BS,
blood sugar; CCB, calcium channel blocker; SGLT2, sodium-dependent
glucose cotransporter 2; UCr, urine creatinine; USug, urine sugar.
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crease glycosuria and dehydration particularly in the aging
patient population.
This case report also indicates another important aspect
of SGLT2 therapy. SGLT2 inhibition is reported to reduce
the threshold of glycosuria from 180mg/dL plasma glu-
cose to 21mg/dL plasma glucose [8]. However, here, in
spite of the normal glucose tolerance there was no effect
on plasma glucose (Table 1) nor did we observe any indi-
cation of a hypoglycemic episode. Thus, the compensation
of the liver by increasing gluconeogenesis apparently
contributed to the protection against hypoglycemia in
this patient. In fact, recently dapagliflozin treatment was
reported to increase endogenous glucose production [9].
Therefore the balance between insulin sensitivity and
insulin resistance in the liver is very crucial to the clinical
application of SGLT2 inhibitors.
Conclusions
Based on our observation, we speculated that patients
treated with an ARB (candesartan) would probably have
an increased response to SGLT2 inhibitor therapy(ipragliflozin) compared with patients treated with alter-
native hypertensive medications such as CCBs (nifedi-
pine). Care will be required to carefully monitor patients
treated with both ARBs and SGLT2 inhibitors to deter-
mine the extent of drug–drug interactions to increase
glycosuria and dehydration particularly in the aging
patient population.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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